Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00688493 · ClinicalTrials.gov registry record · Phase 1
Effects of Single Oral Dose Dapagliflozin QT Study
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00688493 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 36 participants.
The verdict
NCT00688493, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The main purpose of this study is to examine the effect of dapagliflozin on electronic measures of heart beats in healthy males
Interventions
- DRUG Moxifloxacin
- DRUG Dapagliflozin
- DRUG Placebo to match moxifloxacin and dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2007-07 |
| Est. Completion | 2008-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00688493
The ClinicalTrials.gov registry entry for NCT00688493 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Moxifloxacin is the first listed.
NCT00688493 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00688493 about?
NCT00688493 is a clinical study titled "Effects of Single Oral Dose Dapagliflozin QT Study". The main purpose of this study is to examine the effect of dapagliflozin on electronic measures of heart beats in healthy males
What is the current status of trial NCT00688493?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2007-07. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00688493?
The interventions under investigation include: Moxifloxacin (DRUG), Dapagliflozin (DRUG), Placebo to match moxifloxacin and dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT00688493?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.